<DOC>
	<DOCNO>NCT00023777</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine cytarabine daunorubicin treat old patient acute myeloid leukemia previously treat .</brief_summary>
	<brief_title>S0112 Cytarabine Daunorubicin Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy cytarabine daunorubicin induction chemotherapy old patient previously untreated non-M3 acute myeloid leukemia . - Determine frequency severity toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive induction chemotherapy comprise daunorubicin IV continuously day 1-3 cytarabine IV continuously day 1-7 . Patients may treat second course induction chemotherapy begin day 19 remission achieve time . Patients also receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) IV subcutaneously daily begin day 15 continue blood count recover . Patients achieve remission first second course induction chemotherapy receive consolidation chemotherapy comprise daunorubicin IV continuously day 1 2 cytarabine IV continuously day 1-5 . Beginning early day 19 , patient receive second course consolidation chemotherapy . Patients follow every 3 month 1 year , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : Approximately 30-55 patient accrue study within 8-9 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia ( AML ) No M3 AML blastic transformation chronic myelogenous leukemia Must enrol SWOG9007 S9910 protocols PATIENT CHARACTERISTICS : Age : 56 Performance status : Zubrod 03 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 4 time ULN Renal : Creatinine great 1.5 time ULN OR Creatinine clearance great 40 mL/min Cardiovascular : LVEF least 50 % MUGA scan 2dimensional echocardiogram No unstable cardiac arrhythmia No unstable angina Other : Not pregnant nursing Fertile patient must use effective contraception No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy acute leukemia Prior hydroxyurea control high cell count allow Prior lowdose cytarabine ( le 100 mg/m^2/day ) treatment myelodysplastic syndrome allow At least 30 day since prior chemotherapy recover Concurrent singledose intrathecal chemotherapy allow Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>